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Background. Chronic pancreatitis is one of the main risk factors for pancreatic cancer. In acute and chronic pancreatitis, oxidative
stress is thought to play a key role. In this respect, the recently described mitochondria-targeted antioxidant SkQ1 effectively
scavenges reactive oxygen species at nanomolar concentrations.Therefore, we aimed to characterize the influence of SkQ1 on tissue
injury and pain in acute and chronic pancreatitis.Methods. Both acute and chronic pancreatitis were induced in C57BL/6 mice by
intraperitoneal cerulein injections and treatment with SkQ1 was carried out by peroral applications. Hyperalgesia was assessed by
behavioral observation and measurement of abdominal mechanical sensitivity. Blood serum and pancreatic tissue were harvested
for analysis of lipase and histology. Results. SkQ1 did not influence pain, serological, or histological parameters of tissue injury in
acute pancreatitis. In chronic pancreatitis, a highly significant reduction of pain-related behavior (𝑝 < 0.0001) was evident, but
histological grading revealed increased tissue injury in SkQ1-treated animals (𝑝 = 0.03). Conclusion. After SkQ1 treatment, tissue
injury is not ameliorated in acute pancreatitis and increased in chronic pancreatitis. However, we show an analgesic effect in chronic
pancreatitis. Further studies will need to elucidate the risks and benefits of mitochondria-targeted antioxidants as an analgesic.
1. Introduction
Acute and chronic pancreatitis rank within the most com-
mon causes for hospital admission among gastrointestinal
disorders and represent a significant healthcare burden [1].
Furthermore, chronic pancreatitis represents a key risk factor
predisposing to pancreatic cancer [2]. Despite intensive
efforts, treatment is limited to supportive measures and none
of the therapeutic approaches evaluated up until now have
been shown to ameliorate the course of both acute and
chronic pancreatitis. Oxidative stress has been proposed as
a key pathophysiological factor [3, 4]. A common model of
oxidative stress in pancreatitis suggests that oxidative stress
is the result of cytochrome P450 induction, excess exposure
to bioactivated metabolites, and a deficiency of reduced
glutathione [3]. While evidence from animal studies sug-
gests that antioxidant therapy could reduce inflammatory
processes in pancreatitis [4–6], clinical studies were not able
to demonstrate a relevant therapeutic effect [7, 8].
In chronic pancreatitis, especially, pain is a major clinical
problem that affects up to 90% of patients and severely
impacts quality of life [9, 10]. Furthermore, recurrent
episodes of pancreatitis and pain are a relevant clinical
problem in patients with pancreatic cancer [2]. Historically,
pain in chronic pancreatitis has been thought to be caused
by increased pancreatic pressure and mechanical strictures
[11]. Current research on pain in chronic pancreatitis majorly
focuses on pancreatic neuropathy and pancreatic neuritis
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[12]. In accordance with the hypothesis that oxidative stress
is critically linked to the pathogenesis of chronic pancreatitis
and its symptoms, numerous studies have attempted to
demonstrate an analgesic effect of antioxidants in chronic
pancreatitis [13]. In this respect, a recent Cochrane analysis
demonstrated that antioxidants only slightly reduce pain in
chronic pancreatitis and their clinical value remains unclear
[13].
However, the effect of antioxidants in pancreatitis has
only been evidenced by the use of classical, non-mitochon-
dria-targeted antioxidants. Mitochondria-targeted antioxi-
dants have recently been shown to exert cytoprotective
effects [14–20] in numerous studies and are thought to
be effective at nanomolar concentrations [21]. Within the
cytosol, mitochondria are the only anionic organelles and are
specifically targeted by the cationic group of antioxidants of
this family [22]. In this regard, two antioxidants, SkQ1 [23]
andMitoQ [24], have been the focus of research in the field of
mitochondria-targeted antioxidants. Of these, SkQ1 has been
shown to be effective at lower concentrations [23, 25] and has
been demonstrated to ameliorate trauma-induced neurologi-
cal deficit [16], protect erythrocytes from oxidative hemolysis
[17], reduce TNF-𝛼 induced endothelial damage [18], mod-
ulate angiogenesis [26], and decrease ischemia-reperfusion
injury in liver transplantation [20]. On a molecular level,
the antioxidative effect of SkQ1 relies on plastoquinone, an
electron carrier in photosynthesis [23].
As a highly effective scavenger of reactive oxygen species
(ROS), we hypothesize that the mitochondria-targeted anti-
oxidant SkQ1 [23] would reduce inflammatory cell damage
in mouse models of acute and chronic pancreatitis. As such,
serological and histological parameters were evaluated. Fur-
thermore, we aimed to investigate whether SkQ1 would affect
pancreatitis-associated pain as measured by behavioral pain
testing.
2. Material and Methods
2.1. Animals. Female C57BL/6 mice obtained from Charles
River (Sulzfeld, Germany) were kept in accordance with
regulations of the Federal Republic of Germany with a
12-hour light-dark cycle and food and water ad libitum. All
animal procedures were performed according to local ethical
guidelines and approved by the district government of Upper
Bavaria (55.2-1-54-2532-165-2014). Cerulein (50 𝜇g/kg/injec-
tion in saline; Sigma, Sigma Life Science, St. Louis, USA) or
saline (control) was administered intraperitoneally 8 times
at hourly intervals for the induction of acute pancreatitis.
For experiments on chronic pancreatitis, mice received
cerulein (50 𝜇g/kg/injection in saline) or saline (control) at
five hourly injections of cerulein three times a week over a
period of eight weeks. Antioxidative treatment with SkQ1
(10-(6󸀠-plastoquinonyl)decyltriphenylphosphonium) [27]
was administered perorally with the drinking water at a
dose of 5 nmol/kg body weight per day (on average, a mouse
drank about 5mL of water per day).
For experiments on both acute and chronic pancreatitis,
mice were divided in three groups. GroupA (acute pancreati-
tis (AP) 𝑛 = 8; chronic pancreatitis (CP) 𝑛 = 12) was treated
with 5 nmol/kg SkQ1, group B (AP 𝑛 = 8; CP 𝑛 = 12) was the
untreated control, and group C (AP 𝑛 = 8; CP 𝑛 = 7) was
the sham group, which was injected intraperitoneally with
0.9% NaCl instead of cerulein and was therefore the negative
control group without pancreatitis.
For experiments on acute pancreatitis, mice were pre-
treated with SkQ1 for 8 weeks prior to induction of pancreati-
tis. Mice designated for experiments on chronic pancreatitis
received SkQ1 at the same concentration for 8 weeks in
parallel with induction of pancreatitis.
2.2. Open-Field Test/Vertical Activity. Behavioral measure-
ment of nonevoked pain-related behavior was conducted
as described before [28]. Originally, the open-field test was
developed tomeasure emotionality by qualitative and quanti-
tative measures of locomotion. Here, we focus on the vertical
activity (rearing) as the main outcome parameter. Rearing is
an explorative behavior that has been shown tomirror anxiety
which closely correlates with pain sensation in rodents. Less
vertical activity is, therefore, interpreted as more anxiety and
pain. Briefly, mice were allowed to move freely in a square
box of 70 × 70 × 60 cm. After an accommodation period of
10 minutes, behavior was recorded via a video camera over a
time period of five minutes and vertical activity was deter-
mined by counting the times themice reared up. Between the
observations, the box was thoroughly cleaned with ethanol
to eliminate olfactory cues from previous subjects. Vertical
activity was assessed once before the first administration
of cerulein and once after administration of cerulein was
completed.
2.3. Von Frey’s Test. Mechanical sensitivity and evoked pain-
related behavior was measured using Von Frey’s hairs. The
mice were allowed to move freely in a transparent box of 10 ×
10 × 10 cm placed on a metal-lattice. The boxes were cleaned
with ethanol to eliminate odor fromother subjects. Following
an accommodation period of 10 minutes, the abdomen was
stimulatedwith a series ofVonFrey’s hairs of 0.25, 0.5, 1.0, and
2.0mN with 10 applications each. Reactions to stimulation
with Von Frey’s hairs were graded and a pain score was build.
A response was defined as an arousal reaction and allocated
with one point. Any type of defense or flight reaction was
allocated with two points. A cumulative score representing
the sum of pain scores of all filaments was used to assess
mechanical hypersensitivity.
2.4. Serum Lipase. Blood samples were obtained via ventric-
ular heart puncture before sacrifice. Serum lipase levels were
measured in the central clinical laboratories (Zentrallabor,
Hospital of the University of Munich, Germany) according
to locally defined guidelines.
2.5. Histology. Hematoxylin and eosin staining of paraffin
sectionswas performed according to standard protocols. Sub-
sequently, slides were analyzed by an experienced pathologist
(JN) and assessed according to Spormann’s score [29, 30].
Tissue edema and neutrophil infiltration were both graded
on a scale from zero to three, and parenchymal necrosis and
fat necrosis were separately graded on a scale from zero to































Figure 1: Vertical activity in acute (a) and chronic (b) pancreatitis: displayed are the rearing numbers thatwere counted during the observation
time. While there were no differences between the groups in acute pancreatitis (a), treated mice (SkQ1+) with chronic pancreatitis showed
significantly more activity than the untreated (SkQ1−) and saline controls (sham), suggesting less pain in the treated mice (b). ∗Statistically
significant results (𝑝 < 0.05).
seven.The total score consisted of the sum of scores for tissue
edema, neutrophil infiltration, parenchymal necrosis, and fat
necrosis. Additionally, paraffin sections were stained with
aniline blue to assess the degree of fibrosis.
2.6. Statistical Analysis. Statistical analysis was done using
one-way ANOVA and Tukey’s test for multiple comparisons.
The 𝛼-level was set at 0.05. Results are displayed as means
and their respective standard error of the mean (SEM). Data
analysis was carried out using GraphPad Prism version 6.00




3.1.1. Nonevoked Pain-Related Behavior. The number of
observed rear ups was not statistically significant between
both groups A (39.38±4.09) and B (40.00±3.65) or the sham
group. Additionally, no statistically significant differences
were evident between groups A and B (𝑝 = 0.99). Figure 1(a)
compares the vertical activity of all groups after induction of
acute pancreatitis.
3.1.2. Evoked Pain-Related Behavior. Baseline experiments
did not reveal statistically significant differences between
groups A, B, and C (Figure 2(a)). The cumulative pain scores
of groups A and B were significantly different from the sham
group (Figures 2(b) and 2(c)). However, we detected a ten-
dency towards SkQ1 attenuating evoked pain in mice affected
by pancreatitis. Pain scores for group A were 9.38 ± 0.20
and for group B 10.26 ± 0.27 (𝑝 = 0.08).
3.1.3. Serum Lipase. Serum lipase levels of groups A (1887 ±
247U/L) and B (1856 ± 433U/L) significantly differed from
the sham group (Figure 3(a)). No statistically significant
differences were seen in the comparison of groups A and B
(𝑝 = 0.99). Figure 3(a) provides a graphical display of serum
lipase levels in acute pancreatitis.
3.1.4. Histological Grading. Asmeasured by Spormann’s score
(Figures 4(a) and 7(a)–7(c)), groups A and B displayed
statistically significant differences from the sham group. The
difference between groups A (6.87 ± 1.25) and B (8.00 ±
1.48) was not statistically significant (𝑝 = 0.77; Figures 4(a)
and 7(a)–7(c)). Furthermore, a subanalysis of the parameters
edema, neutrophil infiltration, parenchymal necrosis, and fat
necrosis also did not show statistically significant differences
between groups A and B (Figures 5(a)–5(d)).
3.2. Chronic Pancreatitis
3.2.1. Nonevoked Pain. No statistically significant differences
were evident at baseline measurements between groups A
and B and the sham group. After week four, groups A and
B showed statistically significant differences from the sham
group, while a statistically significant difference between
groups A (28.42 ± 2.82) and B (24.00 ± 3.38) was not seen
(𝑝 = 0.62). Measurement of vertical activity at the end of the
experiment at week eight (Figure 1(b)) revealed significantly
increased vertical activity in group A with rearing of 32.25 ±
2.98 versus 22.17 ± 2.88 in group B (𝑝 = 0.05). While the
mean of group B significantly differed from the sham group,
the mean of group A did not (Figure 1(b)).
3.2.2. Evoked Pain. At baseline, no statistically significant
differences were evident in the pain scores between both
groups A and B and the sham group (Figure 8(a)). Moreover,
mean pain scores between groups A (3.60 ± 0.35) and B
(2.79 ± 0.37) also did not display statistically significant
differences (𝑝 = 0.24; Figure 8(a)). After week four, still no
difference between groups A (6.05 ± 0.50) and B (6.92 ± 0.55)
was detected (𝑝 = 0.44; Figure 8(b)). But both groups A and
B differed significantly from the sham group (Figure 8(b)). At
week eight (Figures 8(c) and 8(d)), the cumulative pain score









































p = 0.08 ∗
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Figure 2: Evoked pain-related behavior measured by Von Frey’s hairs in acute pancreatitis: both baseline and final measurements did not































Figure 3: Serum lipase levels in acute (a) and chronic pancreatitis (b): while mice with acute pancreatitis showed significantly higher levels
of serum lipase than the saline controls, no differences were observed with or without treatment (a). In chronic pancreatitis, mice showed
lower serum lipase levels than the saline controls, reflecting advanced disease. As in acute pancreatitis, no differences were observed in treated
versus untreated mice (b). ∗Statistically significant results (𝑝 < 0.05).

































Figure 4: Histological severity of acute (a) and chronic pancreatitis (b) measured by Spormann’s score: in acute pancreatitis, no differences
were observed in treated versus untreated mice (a). In chronic pancreatitis mice treated with SkQ1 showed a slightly higher tissue damage




























































Figure 5: Subparameters of histological severity in acute pancreatitis as measured by Spormann’s score: neither edema (a) nor neutrophil
infiltration (b) nor parenchymal necrosis (c) nor fat necrosis (d) showed statistically significant differences between the SkQ1+ and SkQ1−
groups. ∗Statistically significant results (𝑝 < 0.05).





























































Figure 6: Subparameters of histological severity in chronic pancreatitis as measured by Spormann’s score: again, none of the subparameters
(edema (a), neutrophil infiltration (b), parenchymal necrosis (c), and fat necrosis (d)) showed statistically significant differences between the
SkQ1+ and SkQ1− groups. ∗Statistically significant results (𝑝 < 0.05).
of group A (6.23 ± 0.39) significantly differed (𝑝 < 0.0001)
from the pain score of group B (9.83 ± 0.70). When the sham
group and groupAwere compared, no statistically significant
difference was evident (𝑝 = 0.72; Figure 8(d)).The pain score
of group B was statistically different from the sham group
(𝑝 < 0.0001).
3.2.3. Serum Lipase. Measurement of serum lipase did not
reveal statistically significant differences between groups A
(16.20 ± 1.00U/L) and B (15.50 ± 0.74U/L; 𝑝 = 0.92;
Figure 3(b)). Both groups A and B displayed statistically sig-
nificant differences from the sham group. Figure 3(b) displays
serum lipase levels of groups A–C.
3.2.4. Histological Grading. Analysis of Spormann’s score
(Figures 4(b) and 7(d)–7(f)) revealed statistically significant
differences between both groupsA andB and the shamgroup.
Spormann’s score of group A was significantly higher than
Spormann’s score of group B (13.40±0.40 versus 11.50±0.58,
resp.; 𝑝 = 0.02; Figures 4(b) and 7(d)–7(f)). No statistically
significant differences were detected with respect to the
subparameters edema, neutrophil infiltration, parenchymal
necrosis, and fat necrosis (Figures 6(a)–6(d)). Anilin staining
for fibrosis confirmed the histological findings (data not
shown).
4. Discussion
Chronic pancreatitis has been identified as amajor risk factor
for pancreatic cancer [2] and despite an abundance of studies
and growing understanding of the pathophysiology of acute
and chronic pancreatitis, there are still no specific therapeutic
options [8, 31]. Experimental and clinical studies suggest a
correlation of the oxidative burden and disease severity in






































































Figure 7: Representative HE staining of pancreatic tissue samples of mice with acute (a–c) and chronic pancreatitis (d–f).
acute pancreatitis [31, 32], which prompted numerous studies
investigating the effect of antioxidants in acute and chronic
pancreatitis [7]. One of the reasons for these disappointing
previous results with antioxidants may be that they were
only insufficiently able to penetrate mitochondria, one of
the major sources for endogenous ROS production. To
date, results are conflicting and, ultimately, do not point
to a curative effect of antioxidants in pancreatitis [7, 8].
Nevertheless, mitochondria-targeted antioxidants have not
been part of these investigations so far. Physiologically, ROS
are byproducts of the mitochondrial oxygen metabolism [33]
and are thought to interfere with apoptosis pathways [34].
In this respect, an imbalance of ROS and cellular antioxida-
tive mechanisms has been linked to the pathogenesis and
progression of acute and chronic pancreatitis. Mitochondria-
targeted antioxidants have been shown to exert antioxidative
effects at nanomolar concentrations insidemitochondria [23]
and thus we hypothesized that scavenging ROS at their
mitochondrial origin would reduce tissue injury in acute and
chronic pancreatitis.
For acute pancreatitis, it has been shown that antioxidants
may have a protective effect when administered as a pretreat-
ment [5]. However, the results of the present study show that
a pretreatment with SkQ1 does not result in reduced pain
or tissue injury in cerulein-induced acute pancreatitis. The
cerulein model for acute pancreatitis is the most frequently
used model; however, it only induces a mild variant of acute
pancreatitis over a very short time period of no more than
10 hours. It may, therefore, be possible that the influence of
ROS and oxidative stress on pain and disease severity in acute
pancreatitis is not as critical as initially hypothesized. SkQ1
exhibits a higher antioxidant activity than another struc-
turally similar antioxidant—MitoQ [35]. Moreover, SkQ1 has
in contrast toMitoQ a very wide therapeutic “window,” in the
order of 103, between its antioxidant and prooxidant effects
[25]. Analogous to the results of the present study, Huang et
al. demonstrated that the mitochondria-targeted antioxidant
MitoQ does not improve tissue injury in a mouse model
of acute pancreatitis [24]. Most interestingly, Huang et al.
reported increased cell death rates inmice treatedwithMitoQ
[24]. When comparing MitoQ to SkQ1, one has to consider
that SkQ1 has a higher affinity to mitochondrial cardiolipin
and has been demonstrated to quench ROS more effectively
thanMitoQ, and its antioxidant actionwas found to be exhib-
ited even at nM concentrations [23, 25]. Taking these data
and the results of Huang et al. [24] into account, a low, purely
antioxidant concentration of 5 nmol/kg SkQ1 was considered
sufficient in the present study. The same concentration has
previously been shown to exert beneficial immunological
effects in healthy [26] and pancreatic cancer bearing mice
[26].
In chronic pancreatitis, pancreata of mice treated with
SkQ1 display an even more severe disease when compared to
untreated mice. In this respect, antioxidants have previously
been described to hinder apoptosis and propel necrosis in
pancreatitis [34]. Thus, a potential shift from apoptosis to
necrosis might serve to explain increased tissue injury in
experiments on chronic pancreatitis. Moreover, our results

























































(d) Cumulative (8 weeks)
Figure 8: Evoked pain-related behavior measured by Von Frey’s hairs in chronic pancreatitis: while baseline measurements did not differ
significantly (a), mice with pancreatitis developed significantly increased pain scores after 4 weeks when compared to the saline controls (b).
After 8 weeks of pancreatitis and 8 weeks of treatment, the SkQ1-treated mice show significantly less pain-related behavior than the untreated
controls (c + d). ∗Statistically significant results (𝑝 < 0.05).
indicate that antioxidants do not only exert cytoprotective
effects by scavenging ROS but rather interfere with a complex
network of cellular messenger and effector proteins.
SkQ1 was not able to attenuate tissue injury in chronic
pancreatitis, but mice treated with SKQ1 showed significantly
less pain-related behavior. Among others, pain in chronic
pancreatitis has been described as the result of peripheral
neuropathy and neural damage [36, 37]. Furthermore, pre-
vious studies on mitochondria-targeted antioxidants clearly
show neuroprotective effects of SkQ1 [16, 19]. We, therefore,
hypothesize that SkQ1 treatment may be able to reduce the
ROS-mediated intrapancreatic neural damage and thereby
reduce pancreatic pain in chronic pancreatitis. In this respect,
a recently published meta-analysis demonstrated a moderate
pain reduction in chronic pancreatitis patients treated with
antioxidants [38, 39]. Thus, an analgesic effect of SkQ1 in
chronic pancreatitis may be postulated. However, this poten-
tial pain relief comes at the expense of increased tissue injury.
The lack of parallelism between reduced pain and worsened
tissue injury supports the hypothesis that the analgesic
effect of SkQ1 is not mediated via inhibition of inflamma-
tory processes within the pancreatic tissue. In this regard,
amelioration of neural damage may be a possible mecha-
nism. In pancreatic cancer, where pancreatic tissue injury
is less important in advanced stages, mitochondria-targeted
antioxidants might be an option as an auxiliary analgesic.
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5. Conclusion
SkQ1 may aid in reducing pain in chronic pancreatitis.
However, tissue injury in acute and chronic pancreatitis is
not diminished by SkQ1. In the case of chronic pancreatitis,
SkQ1 may increase disease severity. Thus, further studies
are needed to identify the mechanism for increased tissue
injury after SKQ1 in chronic pancreatitis and to elucidate the
potential of SKQ1 as an analgesic in this setting.
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